Company intelligence / Profile preview

GRIT Program

Zhuhai, Guangdong, Chinagetgritprogram.com ↗

Ownership: Private
Development stage: Other

Overview

Grit Bio has generated initial clinical and safety data from its CAR-NKT product in autoimmune patients and is running pivotal Phase II trials with its lead TIL candidate GT101. GT201 has cleared IND in both the US and China. The company also presented preclinical breakthroughs at ASGCT 2025 on APC-targeted neoantigen vaccines, nonviral nanoparticle-directed in vivo CAR-T therapies, and LNP-mediated CRISPR/Cas9 gene editing of TILs

Therapeutic areas: OncologyImmunology
Modalities: Tumor-infiltrating lymphocyte therapyCell therapyGene-edited cell therapyNeoantigen cancer vaccinemRNA-based drugsSmall molecule (for gene editing delivery)Lipid nanoparticle delivery therapy
Industry: Biotech

Partnerships

Vitalgen BioPharma Co., Ltd.

Beyond the preview

Go deeper on GRIT Program.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GRIT Program.

Explore the full profile